4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridinium chloride | 1683-23-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridinium chloride
• 英文别名: 4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyridine; hydrochloride；1,2,5,6-tetrahydro-4-(3-trifluoromethyl-phenyl)-pyridine hydrochloride；4-(3-(Trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine hydrochloride；4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine;hydrochloride
• CAS: 1683-23-4
• 化学式: C₁₂H₁₂F₃N*ClH
• 分子量: 263.69
• InChiKey: RJFISGALWPADNA-UHFFFAOYSA-N

物化性质

• 熔点：
  209-211 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridinium chloride 在 盐酸 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (+/-)-endo-6-hydroxy-4-(3-trifluoromethylphenyl)-1-azabicyclo<3.3.1>non-3-ene hydrochloride
  参考文献：
  名称：

  Intramolecular Cyclization with Oxocarbenium Ion. Synthesis of 1-Azabicyclo[3.3.1]nonene and [3.2.1]octene Derivatives

  摘要：

  Hydroxy- and aryl-substituted 1-azabicyclo[3.3.1]nonene and [3.2.1]octene derivatives have been synthesized by the intramolecular cationic cyclization of 4-aryl-1,2,5,6-tetrahydropyridines bearing an acetal moiety in the nitrogen substituent. Factors governing the stereoselectivity of the ring closure step have been disclosed. Two compounds were resolved into the enantiomers and the absolute configuration of one of them was deduced from CD investigations. Among the new compounds substances with valuable antiamnesic effect have been found.

  DOI：

  10.3987/com-94-6975
• 作为产物：
  描述：

  4-[3-(三氟甲基)苯基]-4-哌啶 在 盐酸 作用下， 以 水 为溶剂， 反应 5.0h， 生成 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridinium chloride
  参考文献：
  名称：

  DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS

  摘要：

  本发明涉及到((苯基)-3,6-二氢吡啶-1-基)(桥式哌嗪基)-1-烷酮衍生物和((苯基)-2,5-二氢吡咯-1-基)(桥式哌嗪基)-1-烷酮衍生物，对应于式(I)：其中变量如此处所定义，以及其制备和治疗用途。

  公开号：

  US20110144116A1

文献信息

• Use of ER selective NF-kB inhibitors for the treatment of sepsis
  申请人：Caggiano J. Thomas

  公开号：US20050256132A1

  公开（公告）日：2005-11-17

  The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:

  本发明提供了通过调节与雌激素受体相互作用的配体来调节NF-κB转录，从而治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，优选在无典型雌激素活性的情况下进行。本发明的其他方面涉及治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，包括向患有此类病症的患者施用有效量的式I化合物：
• Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
  申请人：EGIS GYOGYSZERGYAR

  公开号：US20040186170A1

  公开（公告）日：2004-09-23

  The present invention is a piperazinylalkylbenzofuran derivative of the formula 1 wherein R 1 represents a C1-4 alkyl group, R 2 stands for a hydrogen atom, X means an oxygen atom, Y is a hydroxyl group, Z represents a hydrogen atom, Ar′ represents a diphenylmethyl group, a pyridyl group, a partially saturated 5-membered heterocyclic group or a phenyl group, n has a value of 0 or 1, and pharmaceutically suitable acid addition salts thereof.

  该发明涉及一种化合物，为一种哌嗪基烷基苯并呋喃衍生物，其化学式为1，其中R1代表一个C1-4烷基基团，R2代表一个氢原子，X代表一个氧原子，Y代表一个羟基，Z代表一个氢原子，Ar′代表一个二苯甲基基团、一个吡啶基、一个部分饱和的5-成员杂环基团或一个苯基，n的值为0或1，并且其药学上适宜的酸盐。
• Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-&bgr;1
  申请人：Sanofi-Synthelabo

  公开号：US06342505B1

  公开（公告）日：2002-01-29

  The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.

  该发明涉及使用化合物(I)的方法，用于制备用于增加循环、细胞和细胞外TGF-β1水平的药物组合物。
• Method for preparing a tetrahydropyridin derivative
  申请人：Sanofi-Synthelabo

  公开号：US06118006A1

  公开（公告）日：2000-09-12

  The invention relates to a method for the preparation of 1-[2-(2-naphthyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyri dine and its pharmaceutically acceptable salts by reacting 2-(2-bromoethyl)naphthalene with 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its salts, and to a universal method for the preparation of the same product and its salts by the reduction of naphthylacetic acid, treatment of the resulting 2-naphthylethanol with hydrobromic acid and treatment of the 2-(2-bromoethyl)naphthalene with 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its salts.

  该发明涉及一种制备1-[2-(2-萘基)乙基]-4-(3-三氟甲基苯基)-1,2,3,6-四氢吡啶及其药用可接受盐的方法，通过将2-(2-溴乙基)萘烷与4-(3-三氟甲基苯基)-1,2,3,6-四氢吡啶或其盐之一反应来实现，以及通过还原萘乙酸、将产生的2-萘乙醇与氢溴酸处理，以及将2-(2-溴乙基)萘烷与4-(3-三氟甲基苯基)-1,2,3,6-四氢吡啶或其盐之一处理来制备相同产品及其盐的通用方法。
• Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination
  申请人：Sanofi-Synthelabo

  公开号：US06344464B1

  公开（公告）日：2002-02-05

  The invention relates to the use of tetrahydropyridine derivatives of the formula in which: R1 is a halogen or a CF3, (C1-C4)alkyl or (C1-C4)alkoxy group; Y is a nitrogen atom or a CH group; Z′ and Z″ are each hydrogen or a (C1-C3)alkyl group, or one is hydrogen and the other is a hydroxyl group, or the two together are an oxo group; and Z is: a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being: (a) a (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)alkoxycarbonyl(C1-C6)alkoxy group; (b) a group selected from (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino or mono- or di-(C1-C4)alkylamino group; or (c) a group selected from phenyl, phenoxy, phenylamino, N—(C1-C3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl group; a phenyl radical disubstituted by a substituent R2, R2 being a halogen or a hydroxy, methyl, ethyl, (C3-C6)alkyl, (C1-C4)alkoxy or trifluoromethyl group, and by a substituent X, X being as defined above; a 1-naphthyl or 2-naphthyl radical; or a 1-naphthyl or 2-naphthyl radical substituted in the 5-, 6-, 7- and/or 8-positions by one or two hydroxy groups, one or two (C1-C4)alkoxy groups or a 6,7-methylenedioxy group; or Z″ is hydrogen and Z and Z′ are each independently an unsubstituted or mono-, di- or tri-substituted phenyl group, or a pharmaceutically acceptable salt and solvate thereof, for the preparation of pharmaceutical compositions intended for treating diseases which cause demyelination.

  该发明涉及以下公式的四氢吡啶衍生物的使用：其中：R1是卤素或CF3，(C1-C4)烷基或(C1-C4)烷氧基；Y是氮原子或CH基团；Z′和Z″分别是氢或(C1-C3)烷基，或一个是氢而另一个是羟基，或两者一起是氧代基；而Z是：苯基团；一个被取代基X单取代的苯基团，X是：(a) (C1-C6)烷基，(C1-C6)烷氧基，(C3-C7)羧基烷基，(C1-C4)烷氧羰基(C1-C6)烷基，(C3-C7)羧基烷氧基或(C1-C4)烷氧羰基(C1-C6)烷氧基团；(b) 选择自(C3-C7)环烷基，(C3-C7)环烷氧基，(C3-C7)环烷基甲基，(C3-C7)环烷基氨基和环己烯基的基团，该基团可以被卤素，羟基，(C1-C4)烷氧基，羧基，(C1-C4)烷氧羰基，氨基或单取代或双取代的(C1-C4)烷基氨基团取代；或(c) 选择自苯基，苯氧基，苯胺基，N—(C1-C3)烷基-苯胺基，苯甲基，苯乙基，苯羰基，苯硫醚，苯磺酰基，苯亚磺酰基和芳基的基团，该基团可以在苯基上被卤素，CF3，(C1-C4)烷基，(C1-C4)烷氧基，氰基，氨基，单取代或双取代的(C1-C4)烷基氨基，(C1-C4)酰氨基，羧基，(C1-C4)烷氧羰基，氨基羰基，单取代或双取代的(C1-C4)烷基氨基羰基，氨基(C1-C4)烷基，羟基(C1-C4)烷基或卤代(C1-C4)烷基团单取代或多取代；一个被取代基R2二取代的苯基团，R2是卤素或羟基，甲基，乙基，(C3-C6)烷基，(C1-C4)烷氧基或三氟甲基团，并且被定义如上的取代基X；一个1-萘基或2-萘基团；或一个在5、6、7和/或8位被一个或两个羟基，一个或两个(C1-C4)烷氧基或一个6,7-亚甲二氧基基团取代的1-萘基或2-萘基团；或Z″是氢，Z和Z′各自独立地是未取代或单取代，二取代或三取代的苯基团，或其药学上可接受的盐和溶剂，用于制备用于治疗导致髓鞘脱失的疾病的药物组合物。